Everand Logo

Welcome to Everand!

  • STAT

    With new data, a biotech tries to relieve doubts about the durability of its gene therapy for Fabry disease

    AvroBio believes new data could start to alleviate concerns about the durability of the one-time gene therapy that surfaced last fall and ravaged the biotech’s stock price.
    by Adam Feuerstein Feb 06, 2019 2 minutes

    An experimental gene therapy developed by the small biotech Avrobio (AVRO) reduced a type of fat that builds up to toxic levels in the cells and organs of patients with Fabry disease, the company reported Wednesday.

    The newly presented clinical trial data were culled from just three patients born with the rare and sometimes deadly disease. Still, Avrobio believes the new data could start to alleviate concerns about

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
    When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
    STAT1 min read
    STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
    Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
    A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

    Related